Table 1 Clinicopathological characteristics of patients and the distribution of characteristics across the training, validation, and test sets in fold 0
Characteristic | N = 968 | Fold 0 | ||
|---|---|---|---|---|
Training N = 660 | Validation N = 111 | Test N = 197 | ||
Age | ||||
Mean ± SD | 49 ± 9 | 49 ± 9 | 49 ± 9 | 48 ± 9 |
Tumor size | ||||
≤ 2 cm | 414 (43%) | 277 (42%) | 57 (51%) | 80 (41%) |
> 2 cm | 554 (57%) | 383 (58%) | 54 (49%) | 117 (59%) |
LN | ||||
0 | 410 (42%) | 286 (43%) | 40 (36%) | 84 (43%) |
1 ~ 3 | 364 (38%) | 243 (37%) | 43 (39%) | 78 (40%) |
≥ 4 | 194 (20%) | 131 (20%) | 28 (25%) | 35 (18%) |
Clinical stage | ||||
I | 203 (21%) | 145 (22%) | 22 (20%) | 36 (18%) |
II | 564 (58%) | 379 (57%) | 60 (54%) | 125 (63%) |
III | 201 (21%) | 136 (21%) | 29 (26%) | 36 (18%) |
Grade | ||||
1 | 39 (4.0%) | 25 (3.8%) | 3 (2.7%) | 11 (5.6%) |
2 | 554 (57%) | 390 (59%) | 54 (49%) | 110 (56%) |
3 | 375 (39%) | 245 (37%) | 54 (49%) | 76 (39%) |
LVI | ||||
0 | 886 (92%) | 609 (92%) | 100 (90%) | 177 (90%) |
1 | 82 (8.5%) | 51 (7.7%) | 11 (9.9%) | 20 (10%) |
ER | ||||
Mean ± SD | 0.82 ± 0.17 | 0.83 ± 0.16 | 0.81 ± 0.19 | 0.81 ± 0.18 |
PR | ||||
Mean ± SD | 0.60 ± 0.32 | 0.61 ± 0.32 | 0.56 ± 0.34 | 0.60 ± 0.33 |
HER2 | ||||
0 | 263 (27%) | 172 (26%) | 33 (30%) | 58 (29%) |
1 | 705 (73%) | 488 (74%) | 78 (70%) | 139 (71%) |
Ki67 | ||||
Mean ± SD | 0.26 ± 0.17 | 0.26 ± 0.18 | 0.26 ± 0.16 | 0.28 ± 0.17 |
Molecular subtype | ||||
0 | 209 (22%) | 159 (24%) | 23 (21%) | 27 (14%) |
1 | 759 (78%) | 501 (76%) | 88 (79%) | 170 (86%) |
RFS status | ||||
No recurrence | 838 (87%) | 579 (88%) | 90 (81%) | 169 (86%) |
Recurrence | 130 (13%) | 81 (12%) | 21 (19%) | 28 (14%) |